Access Pharmaceutical (AXCS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Access Pharmaceutical (AXCS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lawrence Burg who wrote ()	11/10/1999 10:04:00 AM
From: leigh aulper	of 68

Access Pharmaceuticals, Inc. Announces Commencement of Phase III Studies For Residerm(R) A DALLAS, Nov. 10 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: AXCS) ("Access") today announced that the company's development partner Strakan Ltd. ("Strakan") successfully concluded a Phase II ResiDerm(R) A acne clinical study and has now commenced a Phase III study in Europe. Access' ResiDerm(R) delivery system uses zinc ions to enhance the penetration of topically applied drugs into the skin and the accumulation of drug in the skin. Utilizing the ResiDerm(R) technology offers the prospect of improving the clinical effectiveness and reducing systemic side effects associated with a number of therapies commonly used in dermatology. Kerry P. Gray, President and CEO of Access stated, "Strakan continues to make positive steps developing the ResiDerm(R) technology. Should ResiDerm(R) A, be more effective than standard clindamycin therapy, it will be an important product introduction in a topical acne treatment market with worldwide sales in excess of $700 million. ResiDerm(R) A is the first product being developed utilizing the ResiDerm(R) technology platform. It is anticipated that this delivery system could incorporate other topically applied therapies to offer clinical benefits in the treatment of a variety of skin disorders." Assuming positive clinical results, this study will form the basis for a Product License Application to be submitted to the UK Medicine Control Agency prior to seeking further EU Regulatory approvals. The Phase III study is designed to determine whether ResiDerm(R) A is superior to treatment with the market leading clindamycin containing product. Strakan is currently evaluating its clinical development program to determine the data necessary to support a New Drug Application in the United States.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next